
|Articles|August 28, 2014
- Head and Neck Cancers (Issue 1)
- Volume 1
- Issue 1
Unmet Needs in the Treatment of Thyroid Cancer
Author(s)Lori J. Wirth, MD
Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses areas of unmet need in the field of thyroid cancer.
Advertisement
Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses areas of unmet need in the field of thyroid cancer.
Read about molecular markers and the diagnosis of thyroid cancer > >
Articles in this issue
over 11 years ago
Immunotherapy in Head and Neck Cancersover 11 years ago
Molecular Markers Emerge in the Diagnosis of Thyroid Cancerover 11 years ago
Results of the SELECT Trial in Thyroid Cancerover 11 years ago
Update on Targeted Therapies in Head and Neck CancersAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5







































